Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant ... - Pharmacy Times

September 16, 2024

Pembrolizumab plus chemotherapy in neoadjuvant and adjuvant settings significantly improves OS and pCR rates in high-risk early-stage TNBC, establishing a new standard of care.

Related Clinical Trials

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Reference News

pharmacytimes.com

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant ... - Pharmacy Times

Pembrolizumab plus chemotherapy in neoadjuvant and adjuvant settings significantly improves OS and pCR rates in high-risk early-stage TNBC, establishing a new standard of care.